AZN vs BKD

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The Advanced Deterministic Scorecard reveals a deeply concerning financial profile for Brookdale Senior Living (BKD), with a Piotroski F-Score of just 2/9 indicating severe weakness in fundamental health. Despite strong recent price performance (+163.2% over 1Y), the company is unprofitable (ROE: -212.27%, Profit Margin: -9.95%), carries significant liquidity risk (Current Ratio: 0.84), and has consistently missed earnings estimates—0 out of the last 4 quarters beaten, with an average surprise of -101.87%. Valuation metrics are distorted (Price/Book: -462.50, Forward P/E: -23.33) due to negative equity and earnings, while the lack of an Altman Z-Score suggests potential distress risk. Analysts rate it a 'strong_buy' but with only 4 analysts and no meaningful insider activity, the bullish sentiment lacks conviction.